Table 5.
Risk factors for appearance of de novo C1q-binding DSA
| Variable | No C1q+ dnDSAs | C1q+ dnDSA | Odds Ratio Univariate Analysis (95% CI) | P Value | Odds Ratio Multivariate Analysis (95% CI) | P Value |
|---|---|---|---|---|---|---|
| Sex | 0.06 | |||||
| Female | 92 (27.7) | 1 (7.1) | 1 | |||
| Male | 240 (72.3) | 13 (92.9) | 4.98 (0.97 to 91.12) | |||
| Recipient age (yr) | 47.5±12.6 | 41.4±14.4 | 0.12 (0.01 to 1.40) | 0.09 | ||
| Time on dialysis (mo) | 31.3±31.2 | 34.7±29.1 | 2.27 (0.01 to 73.62) | 0.7 | ||
| Extended-criteria donor | 0.5 | |||||
| No | 252 (78.7) | 10 (71.4) | 1 | |||
| Yes | 68 (21.3) | 4 (28.6) | 1.48 (0.39 to 4.58) | |||
| No. of HLA A-B-DR-DQ mismatches | 2.5±1.3 | 3.9±1.1 | 2.22 (1.45 to 3.59) | 0.0002 | 2.19 (1.37 to 3.72) | 0.001 |
| No. of HLA DQ mismatches | 0.5±0.5 | 1.1±0.6 | 6.14 (2.35 to 17.49) | 0.0002 | 4.08 (1.37 to 13.31) | 0.01 |
| Cold ischemia time (h) | 18.5±7.8 | 16.5±10.3 | 0.27 (0.01 to 3.85) | 0.4 | ||
| Induction | 0.9 | |||||
| No induction | 84 (25.3) | 3 (21.4) | 1 | |||
| Daclizumab | 203 (61.1) | 9 (64.3) | 1.24 (0.36 to 5.69) | |||
| Antithymocyte globulins | 45 (13.6) | 2 (14.3) | 1.24 (1.16 to 7.77) | |||
| Tacrolimus versus cyclosporine A at transplantation | 110 (33.3) | 1 (7.1) | 1 | 0.03 | 1 | |
| 217 (65.8) | 12 (85.7) | 6.08 (1.17 to 111.48) | 7.62 (1.34 to 145.20) | 0.02 | ||
| MMF versus azathioprine at transplantation | 299 (90.6) | 13 (92.8) | 1 | 0.8 | ||
| 29 (8.8) | 1 (7.1) | 0.79 (0.04 to 4.20) | ||||
| Delayed graft function | 0.4 | |||||
| No | 253 (76.7) | 12 (85.7) | 1 | |||
| Yes | 77 (23.3) | 2 (14.3) | 0.54 (0.08 to 2.06) | |||
| Tacrolimus versus cyclosporine A at 2 yr | 160 (48.6) | 4 (30.8) | 1 | 0.3 | ||
| 161 (48.9) | 8 (61.5) | 1.98 (0.61 to 7.56) | ||||
| MMF versus azathioprine at 2 yr | 284 (90.4) | 12 (85.7) | 1 | 0.6 | ||
| 30 (9.6) | 2 (14.3) | 1.57 (0.23 to 6.15) | ||||
| Steroid withdrawal at 2 yr | 0.5 | |||||
| No | 168 (51.8) | 6 (42.9) | 1 | |||
| Yes | 156 (48.2) | 8 (57.1) | 1.44 (0.48 to 4.44) | |||
| Borderline rejection before 2 yr | 0.2 | |||||
| No | 312 (94.0) | 14 (100) | 1 | |||
| Yes | 20 (6.0) | 0 (0) | 0.01 (0.00 to 2.40) | |||
| TCMR before 2 yr | 0.8 | |||||
| No | 291 (87.6) | 12 (85.7) | 1 | |||
| Yes | 41 (12.3) | 2 (14.3) | 1.18 (0.18 to 4.54) | |||
| Acute clinical AMR before 2 yr | 0.2 | |||||
| No | 328 (99%) | 13 (93%) | 1 | |||
| Yes | 4 (1%) | 1 (7%) | 6.30 (0.31 to 46.56) |
Unless otherwise noted, values are the number (percentage). Values expressed with a plus/minus sign are the mean±SD. MMF, mycophenolate mofetil; TCMR, T cell–mediated rejection; 95% CI, 95% confidence interval.